These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24707943)

  • 21. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
    Li Z; Li F; Yi S; Gu Z; Yu Z; Xu Y; Feng X; Liu W; Zou D; Qi J; Zhan F; Qiu L
    BMC Cancer; 2015 Jul; 15():555. PubMed ID: 26219471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.
    Jones JA; Ruppert AS; Zhao W; Lin TS; Rai K; Peterson B; Larson RA; Marcucci G; Heerema NA; Byrd JC
    Leuk Lymphoma; 2013 Dec; 54(12):2654-9. PubMed ID: 23547837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
    Gritti G; Reda G; Maura F; Piciocchi A; Baldini L; Molica S; Neri A; Cortelezzi A
    Leuk Lymphoma; 2012 Mar; 53(3):424-9. PubMed ID: 21919823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.
    Lin TS; Flinn IW; Lucas MS; Porcu P; Sickler J; Moran ME; Lucas DM; Heerema NA; Grever MR; Byrd JC
    Leukemia; 2005 Jul; 19(7):1207-10. PubMed ID: 15858611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.
    Winqvist M; Mozaffari F; Palma M; Eketorp Sylvan S; Hansson L; Mellstedt H; Österborg A; Lundin J
    Cancer Immunol Immunother; 2017 Jan; 66(1):91-102. PubMed ID: 27815572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
    Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
    J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
    Keating MJ; O'Brien S; Albitar M; Lerner S; Plunkett W; Giles F; Andreeff M; Cortes J; Faderl S; Thomas D; Koller C; Wierda W; Detry MA; Lynn A; Kantarjian H
    J Clin Oncol; 2005 Jun; 23(18):4079-88. PubMed ID: 15767648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.
    Hillmen P; Skotnicki AB; Robak T; Jaksic B; Dmoszynska A; Wu J; Sirard C; Mayer J
    J Clin Oncol; 2007 Dec; 25(35):5616-23. PubMed ID: 17984186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).
    Wendtner CM; Ritgen M; Schweighofer CD; Fingerle-Rowson G; Campe H; Jäger G; Eichhorst B; Busch R; Diem H; Engert A; Stilgenbauer S; Döhner H; Kneba M; Emmerich B; Hallek M;
    Leukemia; 2004 Jun; 18(6):1093-101. PubMed ID: 15071604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.
    Kay NE; Strati P; LaPlant BR; Leis JF; Nikcevich D; Call TG; Pettinger AM; Lesnick CE; Hanson CA; Shanafelt TD
    Oncotarget; 2016 Nov; 7(48):78269-78280. PubMed ID: 27861157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.
    Mauro FR; Molica S; Laurenti L; Cortelezzi A; Carella AM; Zaja F; Chiarenza A; Angrilli F; Nobile F; Marasca R; Musolino C; Brugiatelli M; Piciocchi A; Vignetti M; Fazi P; Gentile G; De Propris MS; Della Starza I; Marinelli M; Chiaretti S; Del Giudice I; Nanni M; Albano F; Cuneo A; Guarini A; Foà R;
    Leuk Res; 2014 Feb; 38(2):198-203. PubMed ID: 24314589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
    Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M
    N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.
    Varghese AM; Howard DR; Pocock C; Rawstron AC; Follows G; McCarthy H; Dearden C; Fegan C; Milligan D; Smith AF; Gregory W; Hillmen P;
    Br J Haematol; 2017 Feb; 176(4):573-582. PubMed ID: 28032335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.
    Thompson PA; Stingo F; Keating MJ; Ferrajoli A; Burger JA; Wierda WG; Kadia TM; O'Brien SM
    Cancer; 2016 Aug; 122(16):2505-11. PubMed ID: 27182988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patients.
    Oberic L; Vaillant W; Hebraud B; Recher C; Suc E; Houyau P; Laurent G; Ysebaert L
    Eur J Haematol; 2015 Jan; 94(1):37-42. PubMed ID: 24939411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia.
    Cheng MM; Goulart B; Veenstra DL; Blough DK; Devine EB
    Cancer Treat Rev; 2012 Dec; 38(8):1004-11. PubMed ID: 22405931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.
    Fiegl M; Falkner F; Steurer M; Zojer N; Hopfinger G; Haslbauer F; Winder G; Voskova D; Andel J; Lang A; Brychtova Y; Mayer J; Greil R; Gastl G; ; ;
    Ann Hematol; 2011 Sep; 90(9):1083-91. PubMed ID: 21350830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience.
    Sciumè M; Vincenti D; Reda G; Orofino N; Cassin R; Giannarelli D; Gaidano G; Rossi D; Cortelezzi A
    Am J Hematol; 2015 Nov; 90(11):970-4. PubMed ID: 26201283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
    Munir T; Howard DR; McParland L; Pocock C; Rawstron AC; Hockaday A; Varghese A; Hamblin M; Bloor A; Pettitt A; Fegan C; Blundell J; Gribben JG; Phillips D; Hillmen P
    Leukemia; 2017 Oct; 31(10):2085-2093. PubMed ID: 28216660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
    Molica S; Montillo M; Ribatti D; Mirabelli R; Tedeschi A; Ricci F; Veronese S; Vacca A; Morra E
    Haematologica; 2007 Oct; 92(10):1367-74. PubMed ID: 17768114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.